Watson Moves Reps To Women's, General Divisions For Branded Launches
Executive Summary
Watson Pharmaceuticals is shifting sales reps from its dermatology division to support product launches in its general products and women's health divisions.
You may also be interested in...
Synthroid Losing Scripts To Unithroid After "False" Watson Claims - Abbott
Physicians are switching patients from Abbott's Synthroid to Watson's Unithroid as a result of Watson's "false" promotional claims about its levothyroxine product, Abbott said in a lawsuit.
Synthroid Losing Scripts To Unithroid After "False" Watson Claims - Abbott
Physicians are switching patients from Abbott's Synthroid to Watson's Unithroid as a result of Watson's "false" promotional claims about its levothyroxine product, Abbott said in a lawsuit.
King Levoxyl NDA Approval Anticipated In May Ahead of FDA August Deadline
King expects FDA to approve its Levoxyl NDA by the end of May, the company's President and Chief Operating Officer Jeff Gregory said during a conference call Feb. 20.